>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:

  • PETS -9.2%, CADE -8.2%, CALM -5.8%, SOI -1.1%, LII -0.9%

Other news:

  • NTEC -78.9% (announces top-line data from Phase 3 trial of Accordion Pill-Carbidopa/Levodopa compared with immediate release CD/LD as a treatment for the symptoms of advanced Parkinson's disease -- ACCORDANCE study did not achieve statistical superiority)
  • PAYS -6.5% (files for $150 mln mixed securities shelf offering)
  • MRKR -4.6% (reports interim results of its MultiTAA T Cell Therapy)
  • BHVN -4% (receives Complete Response Letter from the FDA for the 505(b)2 application seeking approval for NURTEC)
  • CASI -3.2% (entered into $30 mln common stock Open Market Sale Agreementf)
  • VNDA -1.8% (FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time related to new drug application for Hetlioz)
  • TELL -1.5% (files for 45,999,999 share common stock offering by holders)
  • ACRE -1% (files for $1.25 bln mixed securities shelf offering)
  • NFLX -0.8% (Cautious view in Barrons) .

Analyst comments:

  • MCFT -3.7% (downgraded to Mkt Perform from Strong Buy at Raymond James)
  • MBUU -2.8% (downgraded to Mkt Perform from Strong Buy at Raymond James)
  • KEYS -2.2% (downgraded to Neutral from Buy at Goldman)
  • BC -1.8% (downgraded to Neutral from Overweight at JP Morgan)
  • WLK -1.7% (downgraded to Reduce from Neutral at Nomura)
  • MRVL -1.6% (downgraded to Neutral from Buy at Goldman)
  • LYB -1.4% (downgraded to Neutral from Buy at Nomura)
  • NDAQ -1.4% (downgraded to Sell from Neutral at Citigroup)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:

  • GNC +5.9%, DVA +5.4%, PHG +4.6%, SALT +1.9%, HAL +1.8%, RPM +1.7%, BOH +0.6%

M&A news:

  • SKIS +112.7% ( to be acquired by Vail Resorts (MTN) for $11.00/share in cash)
  • CDOR +32.6% (to be acquired by NexPoint Hospitality Trust for $11.10 per share)

Select metals/mining stocks trading higher:

  • MT +3.2%, CDE +1.9%, NUE +1.7%, FSM +1.6%, SLV +1.3%, FMS +1.2%, SBGL +1%, AUY +0.9%, AG +0.9%, BHP +0.7%

Other news:

  • ACHN +2.9% (announces 'positive' results from their Phase 1 multiple ascending dose (MAD) study with ACH-5228 outside of the US)
  • BG +2.6% (Bunge, BP plc (BP) to form 50:50 joint venture that will create a leading bioenergy company in Brazil)
  • CTST +2.2% (provides interim update on investigation being undertaken by special committee)
  • XXII +1% (announces the FDA accepted and filed for substantive scientific review Modified Risk Tobacco Product application for exclusive Very Low Nicotine Content cigarettes under VLN brand)
  • DIS +0.8% (Postive view in Barrons)
  • AZN +0.8% (FDA has approved the inclusion of overall survival (OS) data from the Phase III PACIFIC trial in an update to the IMFINZI)

Analyst comments:

  • AMRX +4.7% (upgraded to Outperform from Mkt Perform at SVB Leerink)
  • SFIX +3.3% (upgraded to Buy from Hold at Stifel)
  • MU +2.7% (upgraded to Buy from Neutral at Goldman)
  • LRCX +2.5% (upgraded to Buy from Neutral at Goldman)
  • AMAT +2.3% (upgraded to Buy from Neutral at Goldman and added to Conviction Buy List)
  • CAL +2.2% (upgraded to Positive from Neutral at Susquehanna)
  • KLAC +1.6% (upgraded to Neutral from Sell at Goldman)
  • NEWM +1.5% (upgraded to Buy from Neutral at Citigroup)
  • SCHW +1.3% (upgraded to Outperform from Market Perform at Wells Fargo)

>>> US Early premarket gappers

Early premarket gappers

Gapping up:

  • GNC +15%, AMRX +6.8%, GLPG +4.1%, MU +3.4%, MT +3.2%, CDE +3.2%, FSLR +3.1%, FSM +2.9%, LRCX +2.8%, BG +2.6%, AMAT +2.5%, KLAC +2%, APA +2%, NLY +1.7%, FMS +1.7%, DB +1.7%, CS +1.5%, SCHW +1.3%, NUE +1.2%, CHK +1.2%, YNDX +1.2%, AMD +1.2%, ALV +1.2%, SLV +1.2%, HAL +1%, WDC +0.9%, AAPL +0.9%, DIS +0.8%, F +0.8%

Gapping down:

  • EXPR -5.3%, CADE -4.2%, CALM -3.4%, BC -1.8%, WB -1.2%, TEVA -1.1%, AG -1%, LOGI -0.9%, HMY -0.8%, W -0.7%, RGLD -0.5%

NYT : Start-Up Says It’s Changing Eye Care for the Better. Others See It Differe

Start-Up Says It’s Changing Eye Care for the Better. Others See It Differently.
Hubble offers customers contact lens subscriptions at low monthly prices. Critics say it bypasses eye care professionals, doesn’t properly vet prescriptions and takes advantage of federal regulations to the detriment of consumers.

The colorful ads on Facebook and Instagram promise a fantastic bargain: “Stop overpaying for contact lenses. Get 30 contacts delivered to your door for ONLY $1.” Captions like “wow” and “what a steal” splash across images of teal containers and lenses perched on fingertips, urging consumers to act fast.

This social media marketing has been integral to the growth of the online contact lens start-up Hubble since its founding in 2016. It has raised more than $70 million from venture firms and companies like Colgate-Palmolive, which are attracted to its plan to disrupt the contact lens industry by providing a line of low-cost daily lenses through monthly $39 subscriptions. It’s like Dollar Shave Club — for eyeballs.

But Hubble’s early success has been criticized by numerous optometrists and ophthalmologists, who say that its direct-to-consumer model bypasses eye care professionals, that it does not properly vet prescriptions and that it takes advantage of federal regulations to sell customers its own brand of contact lenses. The company, they say, switches people out of their prescribed lens brands and into Hubble’s lenses, sometimes to the detriment of consumers. Those lenses, they say, use a material that some consider to be outdated and can sometimes not fit properly.


The company says its sales are legal. And plenty of customers seem happy with the product. But others have developed eye issues after using the lenses.

Bailey Brown, a 31-year-old in Dallas, developed a corneal ulcer in June. When she was treated at an ophthalmologist’s office, they asked about her lenses. “I said Hubble and they said, ‘Oh, that’s it. You’re not the first,’” she said.

Dr. Lauren Lodholz, an optometrist who practices in Lexington, Ky., said that she had seen complications in more than half of her patients who say they got their lenses from Hubble.

“They’re just assuming the lenses they get from Hubble are the same thing I prescribe them,” Dr. Lodholz said. “They see it’s a great price and see the bottom line.”

Contact lenses are typically fitted, prescribed and sold by optometrists, who often specify brands from major manufacturers like Acuvue Oasys or Biofinity Toric in prescriptions. Sellers can substitute another brand for the lens on the prescription, but only if the substitute lens is the identical product from the same manufacturer. (Some manufacturers make lenses that are sold under different names at retail chains.) Brands like Hubble can also be prescribed.

Editors’ Picks

LeBron James Jr. Is 14. He Already Draws Curious Crowds.

Bob Dylan and the Myth of Boomer Idealism

Don’t Scoff at Influencers. They’re Taking Over the World.
Other companies like 1-800-Contacts also sell major contact brands to consumers, filling orders through copies of prescriptions or getting the prescription information and confirming its accuracy with the consumer’s eye care practitioner.

The Federal Trade Commission, which oversees the market, allows what is known as “passive verification.” Under this method, sellers can try to verify prescriptions through faxes and voice messages and, if eye doctors don’t respond within eight business hours, the orders can be filled. The rule was created in the early 2000s, when companies like 1-800-Contacts pushed to sell brand-name lenses and ran up against eye doctors who did not want to work with them.

Hubble — and its founders and co-chief executives, Ben Cogan and Jesse Horwitz — saw an opportunity in the rule.

A sudden jump in Mr. Cogan’s lens prices in 2015 led to the idea for Hubble — monthly shipments of daily lenses that cost roughly $1 a day. (Prices have since increased.) At the time, he was working for Harry’s, the subscription razor brand, while Mr. Horwitz was on the investment team for Columbia University’s endowment fund.

“It was one of three or four or five things I was tinkering around with,” Mr. Horwitz said at a conference in January, “and we said for all of them, anything that I can go actually raise a seed round for and sort of have investors be stupid alongside me, I’ll go do that one. And so that’s why we did Hubble.”

In December 2015, when Mr. Cogan was seeking a lens manufacturer, he contacted Dr. Sally Dillehay, who was then the chief medical officer at a small lens company and has worked in the contact lens industry for more than 30 years. During a telephone call, Mr. Cogan laid out a plan to move consumers from their prescribed brands and into a private label brand through passive verification, Dr. Dillehay said. This would put consumers into a new type of lens that the patient’s doctor had not prescribed, she said.

“I told them I did not want to be involved with such a company and described in great detail why contact lenses are not generic items like socks or razors, how even small micron level changes in something such as the edge design can completely alter the fit and safety profile of a contact lens,” said Dr. Dillehay, who now runs a consulting company called ClinTrialSolutions in Georgia.

Hubble, in a written response to questions sent by email, said, “The suggestion that Hubble is engaging in impermissible contact lens substitution is simply not based on the facts or the law, and does not reflect our business practices or the standards by which we operate.”

Hubble declined to make Mr. Cogan or Mr. Horwitz available for an interview. It said it was no different from other online sellers that “routinely use passive verification” to fill orders. Hubble also noted that the F.T.C. does not require online sellers to ask customers to list the lens brand on their prescription.

“All Hubble customers are required to have a current prescription for the daily disposable contact lenses that Hubble offers,” the company said. “Hubble uses industry-standard policies and procedures to verify that customers who sign up for Hubble subscriptions have such valid prescriptions.” It declined to comment on Mr. Cogan’s phone call with Dr. Dillehay and did not say how many eye care professionals in the United States prescribe Hubble’s lenses.

In the past decade, attention has been heaped on hip new direct-to-consumer brands selling everything from razors to mattresses. Such companies have typically been built through social media marketing, often offering lower prices than established competitors and sometimes selling their products through subscriptions. Interest increased with successes like Unilever’s purchase of Dollar Shave Club for $1 billion in 2016.

When it comes to health care, however, a start-up’s bold ambitions can sometimes collide with regulations, doctors and patients.

About 45 million Americans wear contact lenses and an estimated 35 percent wear daily disposables. The market is dominated by brands from Johnson & Johnson, Alcon, CooperVision and Bausch & Lomb, and is tough to crack without support from optometrists. That was part of Hubble’s motivation — lenses, especially daily disposables, can be expensive, and the major manufacturers have been accused of anticompetitive practices in recent years. Many optometrists make money by selling contact lenses.

“This incentivizes eye care providers to both prescribe expensive lenses and thwart the efforts of online sellers to offer more affordable options, neither of which are good for consumers,” Hubble said.

Industry groups like the American Optometric Association, which have long been at odds with sellers like 1-800-Contacts, have been more critical of Hubble. Optometrists have complained that Hubble’s messages seeking verification can be difficult to understand, arrive at odd hours and refer to patients that they have never seen. A December 2017 report on the business news website Quartz detailed multiple instances of Hubble sending lenses to people who had entered fake prescriptions and made up doctor names.

Hubble’s website states that prescriptions “must be tailored to Hubble’s lenses” and that they are made by St. Shine Optical Company, a manufacturer in Taiwan whose products have been cleared by the Food and Drug Administration. Multiple Hubble customers told The Times they simply entered the strength of the lenses they needed and a doctor’s name and received their boxes.

As Hubble’s business has grown, its founders have been feted at advertising industry gatherings in New York and Cannes, France, where executives are keen to learn the ways of brands built on Facebook and Instagram. Hubble has appeared on “disrupter” lists with companies like the direct-to-consumer eyeglasses company Warby Parker and Harry’s and its marketing tactics have been described glowingly in a Harvard Business School case study. Its founders were on Forbes magazine’s 30 Under 30 list of leading young entrepreneurs in manufacturing and industry in 2017. And the company was mentioned prominently in an article in The New York Times Magazine about successful start-ups that built their business through advertising on Facebook.

Last year, Colgate-Palmolive took what it described as a “very small, passive stake” in the company. Hubble is providing marketing support to Colgate’s direct-to-consumer “oral care efforts” in the United States.

Investors have viewed Mr. Horwitz and Mr. Cogan as bright entrepreneurs taking on an entrenched industry — and with the law on their side. A 2017 review of Hubble by the venture firm FirstMark Capital, which was obtained by The Times, noted that the company’s dependence on passive verification was a risk but that the rule was likely to stay in place despite “constant attack by optometrists and sympathetic politicians.”

In May, the F.T.C., which has been reviewing its contact lens sales rules, made public a proposal to modify its regulations. It expressed concern “with what appears to be the use of prescription verification to change consumers from their prescribed lens to another brand of lens entirely.” It specifically referred to the rise of new companies reaching consumers through ads on Facebook. If a seller knows or should know that the verification request includes a different brand and manufacturer than what a patient was prescribed, that request is not valid, the agency said.

The F.T.C., which did not mention Hubble, said it believed that this type of “illegal substitution” was growing quickly and acknowledged anecdotal reports of eye injury from patients wearing lenses that weren’t prescribed for them. When contacted for this article, the agency said it did not comment on specific companies. Hubble said that the F.T.C. has never “specifically claimed” that an online seller using its allowed verification methods “is nonetheless engaged in impermissible contact lens substitution.”

Some contact lens fitters and industry experts say that the hydrogel material used by Hubble is outdated and could cause particular discomfort for lens wearers with dry or sensitive eyes. Hubble, in its statement, referred to a recent study of daily disposable lenses that said there were “no clinically significant differences” between hydrogel lenses and ones made with silicone hydrogel, which is used in more expensive lenses.

Dr. Dillehay said that complications could emerge from the absence of fittings and doctor involvement. “If this lens was never seen on someone’s eye, regardless of material, it may never have been the proper lens for that patient,” she said.

The Times interviewed eight people who complained of eye problems after ordering Hubble’s lenses online and the mother of a teenager who wore the lenses. One Hubble user, Ashley McCormick, 20, of Hackensack, Minn., said she woke up one morning in January, barely able to open one eye and seeing flashes of light. Doctors at the emergency room told her that Hubble’s lens material was problematic for her sensitive eyes and that the situation had worsened over several months of daily use. She was diagnosed with uveitis, an inflammation inside the eye.

“By the time I put them in the following morning, even if it was a new pair, my eye wasn’t healing fast enough,” Ms. McCormick said. She said that she had not been aware that the lenses were significantly different from what her eye doctor previously prescribed and estimated that the problem cost her $1,000 in doctor visits, prescription eye drops, gas and lost wages.

“The convenience and affordability of Hubble’s subscriptions encourage customers to engage in healthy practices, instead of overwearing lenses to save money or to avoid the inconvenience of obtaining additional lenses if they run out,” Hubble said in its statement. “Hubble believes that patients should not have to choose between their eye health and their wallet.”

The F.T.C. has received 279 complaints about Hubble and Vision Path, its parent company, since 2016, according to a Freedom of Information Act request. Some of those complaints came from consumers who struggled to stop their subscriptions after signing up for an advertised free trial.

An investor presentation in January 2017 by Hubble outlined several new “retention initiatives.” The company said it switched to phone-only cancellations from 9 a.m. to 6 p.m. on weekdays and suspended emails, like notifications about a customer’s first paid order following a free trial, that were “reminding” people to cancel their subscriptions.

Critics, like the American Optometric Association, say this is another example of Hubble putting profits before patients.

“When you go to Hubble’s website, they’re not promoting good eye health and frequent eye exams and all the things necessary for good vision, they’re only promoting sales of what they do,” said Dr. Samuel Pierce, the former president of the industry group. “Every doctor I know, their goal is to make sure their patients have healthy eyes and the best vision possible.”

NYT : Chinese Money in the U.S. Dries Up as Trade War Drags On

Chinese Money in the U.S. Dries Up as Trade War Drags On

WASHINGTON — Growing distrust between the United States and China has slowed the once steady flow of Chinese cash into America, with Chinese investment plummeting by nearly 90 percent since President Trump took office.

The falloff, which is being felt broadly across the economy, stems from tougher regulatory scrutiny in the United States and a less hospitable climate toward Chinese investment, as well as Beijing’s tightened limits on foreign spending. It is affecting a range of industries including Silicon Valley start-ups, the Manhattan real estate market and state governments that spent years wooing Chinese investment, underscoring how the world’s two largest economies are beginning to decouple after years of increasing integration.

“The fact that the foreign direct investment has fallen so sharply is symbolic of how badly the economic relationship between the United States and China has deteriorated,” said Eswar Prasad, former head of the International Monetary Fund’s China division. “The U.S. doesn’t trust the Chinese, and China doesn’t trust the U.S.”

For years, Chinese investment into the United States had been accelerating, with money pouring into autos, tech, energy and agriculture and fueling new jobs in Michigan, South Carolina, Missouri, Texas and other states. As China’s economy boomed, state and local governments along with American companies looked to snap up some of those Chinese funds.

Sign Up for On Politics With Lisa Lerer
A spotlight on the people reshaping our politics. A conversation with voters across the country. And a guiding hand through the endless news cycle, telling you what you really need to know.

SIGN UP
But Mr. Trump’s economic Cold War has helped reverse that trend.

Chinese foreign direct investment in the United States fell to $5.4 billion in 2018 from a peak of $46.5 billion in 2016, a drop of 88 percent, according to data from Rhodium Group, an economic research firm. Preliminary figures through April of this year, which account for investments by mainland Chinese companies, suggested only a modest uptick from last year, with transactions valued at $2.8 billion.

“I certainly hear in conversations with investors a lot of concern about whether the U.S. market is still open,” said Rod Hunter, a lawyer at Baker McKenzie who specializes in foreign investment reviews. “You have a potentially chilling effect for Chinese investors.”

A confluence of forces appear to be at play. A slowing economy and stricter capital controls in China have made it more difficult for Chinese investors to buy American, according to trade and mergers and acquisitions advisers. Mr. Trump’s penchant for imposing punishing tariffs on Chinese goods and an increasingly powerful regulatory group that is heavily scrutinizing foreign investment, particularly involving Chinese investors, have also scared businesses in both countries.

China, which has retaliated against American goods with its own tariffs, may also be turning off the investment spigot as punishment for Mr. Trump’s economic crackdown.

Concerns about America’s receptiveness to Chinese investment have been aggravated by a flurry of transactions that collapsed under heavy scrutiny from the Committee on Foreign Investment in the United States. The group, which is headed by the Treasury Department, gained expanded powers in 2018 that allow it to block a broader array of transactions, including minority stakes and investments in sensitive technologies like telecommunications and computing.
.
Shortly after the New Year, China’s HNA Group took a $41 million loss on a glass and aluminum Manhattan high rise after American regulators forced it to sell the property because of security concerns about its proximity to Trump Tower, only a few blocks away.

In March, the Chinese owners of a gay dating app known as Grindr were told by regulators to find a buyer for the company. The Trump administration feared Beijing could use personal information as leverage over American officials.

Those interventions followed prominent cases earlier in Mr. Trump’s term, such as Broadcom’s quashed bid for Qualcomm and the sale of MoneyGram to a unit of the Chinese e-commerce giant Alibaba last year. An agreement involving Lattice Semiconductor and an investment firm with reported ties to the Chinese government was also rejected.

In some cases, the chill has benefited American companies. In June, UnitedHealth bought PatientsLikeMe, a health care technology start-up, after the committee said it was a security risk to allow the company’s Chinese owner to have access to health data. The purchase amount was not disclosed.

But the increased scrutiny is also complicating efforts by American industries to team up with Chinese investors and leading to a retrenchment in certain sectors. The real estate sector, which has been buttressed by investors from China in the last decade, has had a steep falloff as relations sour and as Chinese officials clamp down on foreign real estate investment.

A May report from Cushman & Wakefield noted a “frenzy of disposal activity” among Chinese commercial real estate investors in the United States. In 2018, there were 37 property acquisitions by Chinese buyers worth $2.3 billion, but $3.1 billion of commercial real estate was sold off. The report said that the treatment of HNA and tough trade talk made Chinese investors feel unwelcome.

Chinese investors are also showing less appetite for residential real estate in the United States. Research released recently by the National Association of Realtors found that purchases of homes in America by Chinese buyers declined by 56 percent to $13.4 billion in the year to March.

“The magnitude of the decline is quite striking, implying less confidence in owning a property in the U.S.,” said Lawrence Yun, chief economist at the realtor’s group.

Despite the decline, China was still the top foreign buyer of American properties from April 2018 to March 2019.

The financial sector, including banks and private equity, is also feeling the effects. A fund that Goldman Sachs started with the China Investment Corporation in 2017 is being looked at closely by the Treasury Department, according to two Treasury officials. The fund, the China-US Industrial Cooperation Partnership, was set up to invest in American manufacturing and health care companies and then forge business ties in China.

A Goldman Sachs spokeswoman said that the bank was in compliance with all government regulations.

John Kabealo, a Washington-based lawyer who specializes in cross-border transactions, said that American private equity funds are now less likely to team up with foreign funds when making acquisitions because doing so could raise red flags.

“I think there’s a whole lot of concern in the fund world right now,” Mr. Kabealo said. “Funds still want to take Chinese money, but they’re being much more cautious in the way that they do it.”

Even if the two countries reach a trade deal, tepid Chinese investment is expected to continue. The administration is rolling out new barriers to investment, including controls on the types of American technology that can be sold overseas and placing Chinese firms like Huawei on a government blacklist.

The Committee on Foreign Investment in the United States, which previously only had the authority to review transactions in which a foreign investor took a controlling stake of an American business, is now reviewing a broader range of transactions, including joint ventures and smaller investments by foreigners in American businesses that make critical technology.

“There’s certainly a degree of hesitation in China in investing in the U.S.,” said Aimen Mir, the former assistant secretary for investment security at the Treasury Department who recently joined the law firm Freshfields Bruckhaus Deringer. “It’s hard to argue against the fact that these rules have clearly had some impact on Chinese investment.”

Weaker Chinese investment is unlikely to derail the United States economy, as it is a small fraction of that from Britain, Canada, Japan and Germany. China also continues to be largest buyer of United States Treasuries; however, its holdings have fallen in recent years to $1.1 trillion, according to the latest Treasury Department data.

But the decline in investment could hurt areas that are already economically disadvantaged and that have become dependent on Chinese cash. States like Michigan have increasingly wooed Chinese investment, resulting in new factories and jobs in a part of the country that has struggled to recover from the Great Recession.

Craig Allen, the president of the U.S.-China Business Council, said the loss of Chinese investment would be felt predominantly in rural states where Chinese investors have bought factories and revived struggling businesses.

“The not-so-welcome mat is out, and it is having a deleterious effect on relatively poorer areas in the United States that need jobs,” he said.

“The Chinese hear from our state and local officials that they’re welcome,” Mr. Allen said. “What they’re hearing from federal officials is quite different.”

In Kentucky’s Ballard County, local officials are grateful that China’s Shanying International Holdings acquired a closed paper mill last year. In May, the mill reopened and filled many of the 300 jobs that had been lost.

Mayor Brandi Harless of Paducah, Ky., who traveled to China to meet executives of the company this year, said that it would be a shame if trade tensions hampered manufacturing investments in towns such as hers.

“Given our national conversation, I expected there to be some hesitancy,” Ms. Harless said. “But I haven’t heard anyone in our community be negative about this opportunity.”

FT : Iran says it disrupted US spy ring focused on military, nuclear sites

Iran says it disrupted US spy ring focused on military, nuclear sites
Espionage network made up of 17 Iranian nationals, some of whom were sentenced to death

Iran claims it has demolished a spy ring of 17 Iranian nationals who worked in the country’s military and nuclear centres and were trained by US intelligence agents.

An unnamed official in charge of the intelligence ministry’s anti-espionage operations told foreign reporters in Tehran on Monday that the US had expanded its espionage operations inside Iran under President Donald Trump.

He said some of the 17 are sentenced to death while some others co-operated with Iran’s intelligence services to gather information from the US.

Iran revealed the counter-espionage operation in the midst of a crisis sparked by Tehran’s seizure of a UK-flagged tanker on Friday, a bold show of force in retaliation for Britain’s capture of an Iranian vessel earlier this month.

Iranian spies, the intelligence official said, were experts and technicians in “sensitive places” from which the US would like to collect more information. He said this included military and nuclear sites, adding that this network failed to do any major sabotage.

He added that there was no link between CIA and western and regional intelligence services for this operation. But he said some European and non-European countries were aware of the meetings in their countries.

Iran’s operation started last year and it is an ongoing judicial and anti-espionage process, the official said.

Bus. Of Fashion : Will Luxury's Winning Streak Continue?

Will Luxury's Winning Streak Continue?
This week, everyone will be talking about quarterly results from LVMH, Kering and Moncler, Instagram's experiment with hiding 'likes,' and how the UK's new leader will change the Brexit outlook. Read our BoF Professional Cheat Sheet.

  • LVMH and Moncler report results July 24, Kering July 25; shares in all three companies are at or near record highs.
  • Louis Vuitton CEO Michael Burke in June highlighted “unheard of growth rates” for the label in China
  • Richemont, the first major luxury group to release quarterly results, reported a surprise drop in watch sales last week
This week we'll get our quarterly snapshot of the luxury industry. LVMH has signalled that its run of booming sales of leather goods — particularly in China — is nowhere near an end. Barring any surprises on those fronts (not impossible, Richemont did indicate the Hong Kong protests dented watch sales), watch for an indication of how Rihanna's new Fenty ready-to-wear line is performing, and an update on the LVMH's acquisition strategy in the wake of its investment in Stella McCartney. Though still growing fast, Kering faces more pressing questions, including offsetting slowing growth at Gucci and the potential end of the “dad sneaker” craze that supercharged sales at Triple S maker Balenciaga. The answer may lie with struggling Bottega Veneta, where Daniel Lee’s first collection is entering stores. Will he repeat Riccardo Tisci’s strong performance at Burberry?
The Bottom Line: Outside of the big two, Moncler’s results are also worth parsing next week. If the outerwear brand reports another stellar quarter for its strategy of monthly drops, then we can expect more brands to join Tod’s and Calvin Kleinon the list of “Genius” copycats.

>>> Signs two bilateral sustainable revolving credit facilities with Crédit Agri

EDF : Signs two bilateral sustainable revolving credit facilities with Crédit Agricole CIB and Societe Generale CIB, bringing the total of its sustainability-linked loans to over €5B
EDF signed two €300 million sustainability-indexed revolving credit facilities (RCF) which incorporate a pricing adjustment based on EDF’s sustainability performance linked to CO2 emissions and energy efficiency. One facility was signed with the Group Crédit Agricole led by Crédit Agricole CIB including LCL and Crédit Agricole d’Ile-de-France, another one with Societe Generale CIB.
Both RCF incorporate an adjustment mechanism that links the cost of the facilities to three of EDF’s sustainability KPIs: direct CO2 emissions, customers’ use of online consumption monitoring tools (as a proxy of EDF’s success in getting French residential customers actively engaged on their consumption) and electrification of its light vehicle fleet.
With these agreements following on from three previous sustainability-linked loans signed in 2017, 2018 and 2019, EDF confirms that responsible finance instruments play a central role in its financing strategy. RCFs with an ESG indexation now represent a total of over €5 billion, i.e. around 45% of EDF Group credit lines